Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

Neoliensinine improves T-cell malignancy therapy by inducing TUBA1B-mediated lysosomal degradation of STING T-cell ...

-- ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 -- ICT01 has received Orphan Drug Designation from the FDA and EMA; dose selection has ...

Viruses and their hosts—whether bacteria, animals, or humans—are locked in a constant evolutionary arms race. Cells evolve ...

PLT012 is a first-in-class anti-CD36 monoclonal antibody and the first metabolic checkpoint therapy designed to reprogram the tumor microenvironment Phase 1 trial expected to begin in 1Q 2026 ...

Human intestinal M cells function as dendritic cell-like antigen-presenting cells, displaying constitutive MHC-II activity ...

In September, a class action lawsuit was filed against Master Meter and the city of Odessa over allegations that customers were overcharged for water usage. The company and the municipality have filed ...

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...